BAVARIAN NORDIC/S (OTCMKTS:BVNRY) will be posting its quarterly earnings results before the market opens on Wednesday, May 22nd. Analysts expect BAVARIAN NORDIC/S to post earnings of ($0.12) per share for the quarter.
BAVARIAN NORDIC/S stock opened at $6.64 on Wednesday. BAVARIAN NORDIC/S has a 52-week low of $5.92 and a 52-week high of $10.78. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.84 and a current ratio of 6.15.
Separately, Zacks Investment Research downgraded shares of BAVARIAN NORDIC/S from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2019/05/15/bavarian-nordic-s-bvnry-to-release-earnings-on-wednesday.html.
BAVARIAN NORDIC/S Company Profile
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.
See Also: Marijuana Stocks
Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.